Clinical trials: Viral Diseases
HIV Infections
Imaging Immune Activation in HIV by PET-MR
This is a single center exploratory imaging study involving one intravenous microdose of [18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine…
- Trial name
- NCT03684655
- Testing
- [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- CellSight Technologies, Inc.
Molluscum Contagiosum
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution [0.7% (w/v) cantharidin] (VP-102) when…
- Trial name
- NCT03186378
- Testing
- VP-102 with applicator
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Verrica Pharmaceuticals Inc.
Covid-19
Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
The aim of this study is to explore potential for reduction of incidence and/or morbidity of SARS-CoV-2 infection in healthcare personnel. The study will include a comparison between placebo and RUTI® vaccine in a 2:1 design.
- Trial name
- NCT04903184
- Testing
- RUTI® vaccine
- Where
- 6 sites in Argentina
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- RUTI Immunotherapeutics S.L.
Chronic Hepatitis C
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
- Trial name
- NCT00722358
- Testing
- BMS-650032
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
COVID-19
A Study to Determine the Tolerability of Intranasal LMN-301
LMN-301 is to prevent infection by severe acute respiratory syndrome-corona virus (SARS-CoV-2) (the virus causing coronavirus disease of 2019 (COVID-19) in uninfected individuals.
- Trial name
- NCT06030414
- Testing
- LMN-301
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Hepatitis C
Trial of Hepatitis C Self-Testing in the Hands of Untrained Lay Users
This is a controlled study intended to evaluate the usability, label comprehension and performance of the INSTI® HCV Self Test in the hands of untrained lay users using fingerstick blood, with instructions for use specifically…
- Trial name
- NCT06369116
- Testing
- INSTI HCV Self Test
- Where
- South Africa
- Volunteers
- 1,415 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Influenza
A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00375206
- Testing
- Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)
- Where
- 2 sites in United States
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- PowderMed
Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been…
- Trial name
- NCT06581406
- Testing
- RP2, Ipilimumab, Nivolumab
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 280 people
- Sponsor
- Replimune, Inc.
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
COVID-19
Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
- Trial name
- NCT04883138
- Testing
- GIGA-2050
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GigaGen, Inc.
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose levels of IMO-2125 in combination with standard weight based ribavirin (investigational treatment arm) or placebo in combination with…
- Trial name
- NCT00990938
- Testing
- IMO-2125, Saline
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Coronavirus Infection
Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients
Study on adult patients positive to COVID-19 virus. After signing informed consent and undergoing screening assessments, eligible patients will record few times a day several pre-defined sentences to the Cordio App installed in a…
- Trial name
- NCT04325048
- Testing
- Cordio App
- Where
- Israel
- Volunteers
- 42 people
- Sponsor
- Cordio Medical
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT01153685
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an…
- Trial name
- NCT00002435
- Testing
- Thymic Humoral Factor, Zidovudine
- Where
- 10 sites in United States
- Sponsor
- Pharmacia
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Chronic Hepatitis C
Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)
This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK) of uprifosbuvir (MK-3682/IDX21437) in healthy participants and in participants infected with Hepatitis C virus (HCV) genotype (GT)1-GT6.
- Trial name
- NCT01974687
- Testing
- Uprifosbuvir, Itraconazole
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Prophylaxis
Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection
The purpose of this study is to determine the safety of motavizumab (MEDI-524) following a single intravenous dose in children hospitalized with respiratory syncytial virus (RSV).
- Trial name
- NCT00192504
- Testing
- Motavizumab
- Volunteers
- 31 people
- Sponsor
- MedImmune LLC
Covid19
Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients
The current study will investigate the tolerability and efficacy of inhaled Carragelose® versus saline in hospitalized COVID-19 patients.
- Trial name
- NCT04793984
- Testing
- Carragelose, NaCl
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Marinomed Biotech AG
HIV Infections
Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)
Compassionate use access to fostemsavir (GSK3684934, formerly BMS-663068) for the treatment of HIV infection in individuals with multidrug resistant HIV-1 infection who are experiencing virologic failure and are unable to…
- Trial name
- NCT04233047
- Testing
- Fostemsavir
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.